ekonominyheter

TranslateRSSMobil
Arena Pharmaceuticals, Inc. Earnings: Looking for More

Arena Pharmaceuticals, Inc. Earnings: Looking for More

Fool.com 3/11 23:48

A prescription growth rate of 30% sounds good, but Belviq has such low sales, it's hard to get too excited yet. If phase 3 trials pan out, long-term growth will likely come from use as a smoking cessation drug and as a combination product for obesity.

Till artikeln

Ekonomi Nyheter .se - Innehåll

 

 

 

 

DMCA.com Protection Status